Cardiovascular outcomes with thiazolidinediones and sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus undergoing peripheral artery revascularization
Authors' conclusion
Among patients with T2DM undergoing peripheral artery revascularization, TZD and SGLT-2i were associated with favourable clinical outcomes compared to DPP-4i.
Study context
- Population
- Patients with T2DM who underwent peripheral artery revascularization (endovascular or surgical), Korean National Health Insurance Claims database (2015–2023)1:3 propensity-matched
- Exposure
- Thiazolidinediones (TZD) vs DPP-4i, and SGLT-2i vs DPP-4i
- Outcome
- Composite of:
- Major adverse limb events (repeated revascularization or amputation)
- Stroke
- MI
- Admission for HF
- All-cause death
Methodological detailsnationwide claims database, 1:3 propensity score matching, stratified Cox regression
- Nationwide claims database
- 1:3 propensity score matching
- Stratified Cox regression
Main finding
As reported in the abstract
Primary composite outcome
Each group vs DPP-4iHazard ratio (95% CI)P value
TZD
0.74(0.63–0.86)
P < 0.001SGLT-2i
0.88(0.79–0.98)
P = 0.015Observational data: associations, not effects.
Secondary outcomes
Major adverse limb events and all-cause death (TZD vs DPP-4i)
- TZD users associated with lower risks of major adverse limb events and all-cause death vs DPP-4i users
All-cause death (SGLT-2i vs DPP-4i)
- SGLT-2i treatment associated with reduced all-cause death
Original publication
Cardiovascular outcomes with thiazolidinediones and sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus undergoing peripheral artery revascularization. Diabetes Res Clin Pract. Published 27 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →